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Background: 1st generation 5-hydroxytryptamine receptor antagonists (5-HT3 RAs), and palonosetron, a 2
nd
generation 5-HT3 RA, are indicated for the prevention of chemotherapy (CT)-induced nausea and vomiting (CINV)
associated with moderately (MEC) and highly emetogenic CT agents (HEC). This study explores the impact of step
therapy policies requiring use of an older 5-HT3 RA before palonosetron on risk of CINV associated with hospital or
emergency department (ED) admissions.
Methods: Patients who received cyclophosphamide post breast cancer (BC) surgery or who were diagnosed with
lung cancer on carboplatin (LC-carboplatin) or cisplatin (LC-cisplatin) were selected from PharMetrics’ (IMS LifeLink)
claims dataset (2005-2008). Patients were followed for 6 months from initial CT administration for CINV events
identified through ICD-9-CM codes. Patients were grouped into those initiated with older, generic 5-HT3 RAs
(ondansetron, granisetron, and dolasetron) and those initiated and maintained on palonosetron throughout study
follow-up. CINV events and CINV days were analyzed using multivariate regressions controlling for demographic
and clinical variables.
Results: Eligible patients numbered 3,606 in BC, 4,497 in LC-carboplatin and 1,154 in LC-cisplatin cohorts, with 52%,
40%, and 34% in the palonosetron group, respectively. There was no significant difference between the two 5-HT3
RA groups in age or Charlson Comorbidity Index among the two MEC cohorts (BC and LC-carboplatin). Among the
LC-cisplatin cohort, palonosetron users were older with more males than the older 5-HT3 RA group (age: 60.1 vs.
61.3; males, 66.9% vs. 56.9%). Compared to the older 5-HT3 RAs, the palonosetron groups incurred 22%-51% fewer
5-HT3 RA pharmacy claims, had fewer patients with CINV events (3.5% vs. 5.5% in BC, 9.5% vs. 12.8% in LC-
carboplatin, 16.4% vs. 21.7% in LC-cisplatin), and had lower risk for CINV events (odds ratios 0.62, 0.71, or 0.71,
respectively; p< 0.05). The BC and LC-carboplatin palonosetron groups experienced 50% and 30% fewer CINV days
than the generic 5-HT3 RA group (p< 0.05).
Conclusions: Patients with breast or lung cancer initiated and maintained on palonosetron were at significantly
lower risk for potentially costly CINV versus those on older 5-HT3 RAs. Further studies on impact of step therapy
policy are warranted in order to minimize the clinical and economic burden of CINV.* Correspondence: hthatoum@sbcglobal.net; deborahbuchner@AOL.com
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Antiemetics including the 5-hydroxytryptamine receptor
antagonists (5-HT3 RAs) have been used as prophylaxis
against chemotherapy-induced nausea and vomiting
(CINV) in patients receiving moderately (MEC) or
highly emetogenic (HEC) chemotherapy [1,2]. Palonose-
tron (Aloxi
W
) is a newer 5-HT3 RA, approved in the US
in 2003 for antiemetic prophylaxis in patients with can-
cer receiving MEC or HEC.
Palonosetron is a potent and highly selective 5-HT3 RA
with a strong binding affinity and a longer plasma-
elimination half-life relative to the older 5-HT3 RAs [3].
Among the 5-HT3 RAs, palonosetron is unique in that
it exhibits allosteric interactions, triggers receptor inter-
nalization, differentially inhibits “crosstalk” between
NK-1 receptors and 5-HT3 signaling pathways, with
prolonged inhibition of receptor function [4,5]. In four
phase III trials, two in MEC and two in HEC, palono-
setron was reported to have improved efficacy relative
to the older 5-HT3 RAs in the prevention of nausea
and vomiting associated with initial and repeat courses
of MEC or HEC [2,6-8]. The available pre-clinical and
clinical evidence suggests that the control of CINV in
the delayed phase is a true pharmacological effect
reflecting the unique properties of palonosetron rather
than a carryover effect from better control during the
acute phase [9].
The step-wise use of medications commonly referred
to as step-therapy is a pharmacy administration
interventional tool employed to encourage the use of
purportedly therapeutically equivalent, but lower-cost
medications from the same or different therapeutic
classes. Studies of step therapy have reported mixed
results in terms of step therapy’s ability to control drug
and total medical expenditures. In fact, several of these
studies have reported that the initial cost savings of
implementing step therapy programs diminished over
time [10-13], resulting in a negative impact on medical
utilization and associated costs [10,11,13]. Moreover, a
recent commissioned report by the Academy of Mana-
ged Care Pharmacy (AMCP), a professional association
of pharmacists and other health care practitioners who
practice pharmaceutical care in managed health care
environments[14], concluded that there is a paucity of
research examining the effects of step therapy on clinical
and humanistic outcomes [15].
Because palonosetron is a newer 5-HT3 RA antiemetic,
oncology practices and managed care institutions may
consider some form of step therapy, whereby an older
and generic 5-HT3 RA would be prescribed as initial
therapy for CINV prophylaxis, reserving palonosetron
for second-line prophylaxis or as rescue medication as a
means to contain costs. The current study assesses the
use of a step therapy-like approach to guide theprescribing choice between palonosetron and the older
5-HT3 RAs as to its potential clinical and economic im-
pact. The objectives of the study were to: 1) identify pat-
terns of therapy with 5-HT3 RA-based antiemetic
regimens indicative of step therapy approaches in
patients newly treated with MEC or HEC, 2) explore the
characteristics of patients and health plans associated
with 5-HT3 RA step therapy prescribing patterns, and 3)
evaluate the impact of a step therapy approach of initiat-
ing patients on an older 5-HT3 RA before using palono-
setron with regard to differences in the incidence of
hospital/emergency department (ED) associated CINV
events.
Methods
The study population was selected from the PharMetrics
(IMS LifeLink) claims database, which compiles inte-
grated managed care pharmacy and medical claims of
over 2 billion inpatient and outpatient transactions from
60 million members in the United States. The database
is longitudinal, going back as far as 1995, and contains
information on paid claims for drugs (drug name, quan-
tity dispensed, length of supply), medical diagnoses, and
procedures, and demographics of each patient. Prescrip-
tion drugs are coded with the National Drug Code
(NDC) from the US Food and Drug Administration.
Diagnoses are coded using the International Classifica-
tion of Diseases-Clinical Modification, 9th Revision
(ICD-9-CM), and procedures are coded using the
Current Procedural Terminology-4 (CPT) and Health-
care Common Procedure Coding System (HCPCS). This
database has been used for many previous studies [16].
The study included patients diagnosed with breast can-
cer (BC) who received adjuvant chemotherapy with cyclo-
phosphamide within four months after surgery, along with
patients diagnosed with lung cancer (LC) who received
carboplatin (LC-carboplatin), and patients diagnosed with
lung cancer (LC) who received cisplatin-based chemother-
apy (LC-cisplatin). The study time frame was from January
1, 2005 through June 2008. Based on the doses used and
the published literature [17], the BC and the LC-
carboplatin cohorts were considered MEC-treated, while
the LC-cisplatin cohort was considered HEC-treated. The
study index date was defined as the first date of BC diag-
nosis for the BC cohort or the first date of chemotherapy
with carboplatin/cisplatin for the LC cohorts. The index
chemotherapy was the first chemotherapy treatment cycle
and the index chemotherapy date was marked as the first
day of the index chemotherapy.
Patients with BC were identified using the ICD-9-CM
codes (174.xx). Patients with LC were identified by ICD-
9-CM codes of 162.xx. NDC and HCPCS codes were
used to identify oral and injectable chemotherapies, re-
spectively. Selected patients were ≥18 years of age having
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date. Additional inclusion criteria included patients not
having prior history of vomiting, nausea, or dehydration
identified by ICD-9-CM codes during the 6 months pre-
ceding the index chemotherapy and patients having a
≥6 months follow-up period after the index chemother-
apy. Study duration was defined as six months from the
index chemotherapy date. Patients who received cyclo-
phosphamide, carboplatin, or cisplatin within the six
months prior to index chemotherapy were excluded.
Antiemetics investigated in this study were dolasetron,
granisetron, ondansetron, and palonosetron. The con-
comitant use of either aprepitant or dexamethasone was
also included within the analytic comparison groups. In-
jectable antiemetics were identified from the HCPCS
codes for inpatient and outpatient claims while those
administered orally were identified through appropriate
NDCs in the prescription drug claims file. Based on the
prescribing patterns of 5-HT3 RAs, patients were classi-
fied in two groups: the palonosetron group consisting of
patients initiated with palonosetron on the index CT
date and maintained on it for the study duration, and
the older 5-HT3 RA group, who were initiated with one
of the first generation 5-HT3 RAs, and then were either
maintained on the initial agent or alternated between
any 5-HT3 RAs (including palonosetron) in the subse-
quent 6-month study duration. The use of aprepitant
and dexamethasone was assessed in both study groups.
Severity of patient conditions identified through
comorbidities during the 6-month baseline period before
the study index date were summarized using the Charlson
Comorbidity Index (CCI), an aggregate measure with
higher scores denoting greater disease burden [18,19].
Health insurance related variables included type of plan
(health maintenance organization, indemnity, preferred
provider organization, point of service, others), type of
payer (commercial, public, self-insured), and pharmacy
benefit plans.
CINV events were extracted using both paid and filed
claims with ICD-9-CM codes for nausea, vomiting, and/
or dehydration (787.0, 787.01, 787.02, 787.03, 276.5,
276.50, 276.51, and 276.52). CINV events associated
with hospital/ED admissions were selected. The identifi-
cation of practice setting (e.g., hospital, ED, physician
office) where a CINV event occurred was based on an
algorithm that employed several variables such as pro-
vider specialties, place of service, and HCPCS codes.
Total days on cyclophosphamide, carboplatin, or cis-
platin within the study duration were also calculated for
the three study cohorts.
Statistical analyses
Descriptive statistics are reported for all variables used
in this study. For continuous variables, t-tests wereperformed to compare palonosetron group to the older
5-HT3 RA group. Nonparametric Wilcoxon tests were
used to compare days with hospitalization/ED related
CINV events and for categorical variables, chi-square
tests were performed to compare between the groups.
Multivariate logistic regression models and Poisson re-
gression models were performed separately for the three
cohorts. Logistic regression models, through backward
elimination, investigated the risk of any occurrence of
hospital/ED associated CINV events, while Poisson
regression models examined the number of days with
hospital/ED associated CINV events. Both regression
models controlled for age, CCI, gender (lung cancer
cohorts only), and days on CT with cyclophosphamide,
carboplatin, or cisplatin. A negative binomial distribu-
tion was used to control for over-dispersion in Poisson
regressions. All statistical analyses were carried out with
SAS 9.0 statistical software (SAS Institute, Inc, Cary,
NC, USA).
Results
Demographic characteristics of the study cohorts
A total of 3,606 patients with BC, 4,497 patients in LC-
carboplatin, and 1,154 in LC-cisplatin cohorts were
included. Among the selected study population, 1,864
(52 %) patients with BC, 1,806 (40%) patients in the LC-
carboplatin and 390 (34%) patients in the LC-cisplatin
cohorts were in the palonosetron group. The mean (SD)
age was 53.7 (9.8) years for the BC cohort, 64.9 (10.2)
years for the LC-carboplatin, and 60.5 (9.8) years for the
LC-cisplatin cohorts. Calculated CCIs at baseline were
0.5 (1.0), 6.8 (3.2), and 6.5 (3.3) in BC, the LC-carboplatin,
and the LC-cisplatin cohorts, respectively.
There were no significant differences between the
older 5-HT3 RA and the palonosetron groups in age and
CCI in the BC and LC-carboplatin cohorts. In the LC-
cisplatin cohort, the palonosetron group was signifi-
cantly older (mean, 61.3 versus 60.1 years, p< 0.05), and
had fewer females (33.3% versus 43.1%, p< 0.005) than
the older 5-HT3 RA group (Table 1).
Health insurance and payer characteristics
More than 90% of the patients in the breast cancer co-
hort and 80% of the patients in the lung cancer cohorts
were insured by commercial payers, most likely reflect-
ing the data source. There were no statistically signifi-
cant differences in the payer mix between the two
comparison groups for all three cancer cohorts (Table 2).
However, there were significant differences found in the
distribution of health plan type between the older 5-HT3
RA and the palonosetron groups. More specifically,
the proportion of patients enrolled in health mainten-
ance organizations (HMO) was lower in the palonose-
tron group compared to the older 5-HT3 RA group
Table 1 Patients and provider characteristics
Breast cancer Carboplatin-treated lung cancer Cisplatin-treated lung cancer
All Older
5-HT3 RAs
Palonosetron P All Older
5-HT3 RAs
Palonosetron P All Older
5-HT3 RAs
Palonosetron P
N 3,606 1,742 1,864 4,497 2,691 1,806 1,154 764 390
Age mean
(SD)
53.7 (9.8) 53.7 (9.7) 53.7 (10.0) NS 64.9 (10.2) 64.77 (10.2) 65.03 (10.3) NS 60.5 (9.8) 60.1 (9.8) 61.3 (9.8) 0.0476
CCI mean
(SD)
0.5 (1.0) 0.5 (1.1) 0.5 (1.0) NS 6.8 (3.2) 6.87 (3.2) 6.71 (3.2) NS 6.5 (3.3) 6.6 (3.3) 6.3 (3.2) NS
Female,
N (%)





2005 1,428 (39.6) 753 (43.3) 675 (36.2) 1,562 (34.7) 990 (36.8) 572 (31.7) 348 (30.2) 247 (32.3) 101 (25.9)
2006 1,537 (42.6) 720 (41.3) 817 (43.8) 1,480 (32.9) 857 (31.9) 623 (34.5) 394 (34.1) 263 (34.4) 131 (33.6)
2007 520 (14.4) 223 (12.8) 297 (15.9) 1,140 (25.4) 687 (25.5) 453 (25.1) 315 (27.3) 194 (25.4) 121 (31.0)
2008 121 (3.4) 46 (2.6) 75 (4.0) 315 (7.0) 157 (5.8) 158 (8.8) 97 (8.4) 60 (7.9) 37 (9.5)
P: P value; CCI: Charlson Comorbidity Index; 5-HT3 RAs: 5-hydroxytryptamine receptor antagonists.
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LC-carboplatin cohort, both at p< 0.0001). Similarly, the
palonosetron group, for both the BC and LC-carboplatin
cohorts, was less likely to have pharmacy benefit type




Palonosetron P All O
5-




Commercial 3,321 (92.1) 1,592 (91.4) 1,729 (92.8) 3,632 (80.8) 2,
Public 167 (4.6) 87 (5.0) 80 (4.3) 715 (15.9) 44
Self-insured 100 (2.8) 54 (3.1) 46 (2.5) 134 (3.0) 84




HMO 813 (22.6) 434 (24.9) 379 (20.3) 1,071 (23.8) 73
Indemnity 320 (8.9) 136 (7.8) 184 (9.9) 854 (19.0) 49
PPO 1,742 (48.3) 792 (45.5) 950 (51.0) 1,982 (44.1) 1,
POS 556 (15.4) 316 (18.1) 240 (12.9) 462 (10.3) 27




No 700 (19.4) 300 (17.2) 400 (21.5) 1,229 (27.3) 65
Yes 2,372 (65.8) 1,198 (68.8) 1,174 (63.0) 2,809 (62.5) 1,
Unknown 534 (14.8) 244 (14.0) 290 (15.6) 459 (10.2) 26
HMO: health maintenance organization, PPO: preferred provider organization, POS:was 63.0% vs. 68.8% in the BC cohort and 57.6% vs.
65.7% in the LC-carboplatin cohort, p< 0.001. No signifi-
cant differences were found in the LC-cisplatin cohort
regarding health plan type or in having a pharmacy
benefit.latin-treated lung cancer Cisplatin-treated lung cancer
lder
HT3 RAs
Palonosetron P All Older
5-HT3 RAs
Palonosetron P
691 1,806 1,154 764 390
NS NS
149 (79.9) 1,483 (82.1) 971 (84.1) 638 (83.5) 333 (85.4)
8 (16.7) 267 (14.8) 121 (10.5) 81 (10.6) 40 (10.3)
(3.1) 50 (2.8) 55 (4.8) 39 (5.1) 16 (4.1)
(0.4) 6 (0.3) 7 (0.6) 6 (0.8) 1 (0.3)
<0.0001 NS
4 (27.3) 337 (18.7) 272 (23.6) 182 (23.8) 90 (23.1)
9 (18.5) 355 (19.7) 170 (14.7) 112 (14.7) 58 (14.9)
114 (41.4) 868 (48.1) 551 (47.8) 360 (47.1) 191 (49.0)
8 (10.3) 184 (10.2) 120 (10.4) 77 (10.1) 43 (11.0)
(2.5) 62 (3.4) 41 (3.6) 33 (4.3) 8 (2.1)
<0.0001 NS
6 (24.4) 573 (31.7) 246 (21.3) 151 (19.8) 95 (24.4)
769 (65.7) 1,040 (57.6) 761 (65.9) 518 (67.8) 243 (62.3)
6 (9.9) 193 (10.7) 147 (12.7) 95 (12.4) 52 (13.3)
point of service, pts: patients.
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During the 6-month study follow-up, the palonosetron
group in the BC and LC-cisplatin cohorts had signifi-
cantly fewer cyclophosphamide or cisplatin treatment
days, as compared to their older 5-HT3 RA groups (4.2
versus 4.3 days in BC, p = 0.0297; and 4.9 versus 6.3 days
in the LC-cisplatin, p< 0.0001, Table 3). Treatment days
with CT were not significantly different between the two
comparison groups in the LC-carboplatin cohort (6.1
versus 6.2 days). The palonosetron group in all three
study cohorts had used significantly less antiemetics
than that used by the older 5-HT3 RA groups. In fact,
the mean number of 5-HT3 RA claims in the BC cohort
was 6.2 in the palonosetron group versus 7.9 in the older
5-HT3 RA group. Similarly, the mean claims were 7.7
and 10.3 for the two comparison groups in the LC-
carboplatin cohort and were 6.4 and 13.1 in the LC-
cisplatin cohort (all P< 0.0001). When the utilization of
aprepitant and dexamethasone were included, the total
number of antiemetic claims in the palonosetron groups
remained significantly lower than the total claims for the
older 5-HT3 RA groups among all three cancer cohort
(all p< 0.0001). On average, the palonosetron group had
22-51% fewer 5-HT3 RA claims, and 16-44% fewer total
antiemetic claims depending on whether the antiemtic
regimens were associated with MEC or HEC.
Unadjusted risk for CINV
Comparing the unadjusted risk for CINV, there were
fewer patients in the palonosetron groups with one or
more hospital/ED associated CINV events than those in
the older 5-HT3 RA groups. The percentage of patients




Palonosetron P* All Older
5-HT3
N 3,606 1,742 186 4,497 2,691
CT tx days,
mean (SD)
4.2 (1.2) 4.3 (1.3) 4.2 (1.2) 0.0297 6.1 (3.7) 6.2 (3.6
All antiemetic
claims
9.1 (5.1) 9.9 (5.5) 8.3 (4.6) <0.0001 10.2 (6.7) 11.4 (7
All 5-HT3 RA
claims










161 (4.5) 95 (5.5) 66 (3.5) 0.0055 516 (11.5) 345 (1
CT: chemotherapy, Tx: treatment, ED: emergency department, pts: patients.
P values were based on t-tests, except for days and proportions of patients with ho
Chi-square tests were used, respectively.group and 5.5% in the older 5-HT3 RA groups for the
BC cohort (p = 0.0055). Similarly, the proportions were
9.5% vs. 12.8% (p = 0.0005) in the LC-carboplatin and
16.4% vs. 21.7% (p = 0.0324) in the LC-cisplatin cohorts,
respectively. Furthermore, patients in the palonosetron
group had significantly fewer days with hospital/ED
associated CINV events than patients in the older, gen-
eric 5-HT3 RA groups with means of 0.06 vs. 0.11 days
among BC patients, 0.24 versus 0.34 in the LC-
carboplatin and 0.57 versus 0.67 in the LC-cisplatin
cohorts, all p< 0.05; Table 3.
Adjusted risk for CINV
In the BC cohort, logistic regression models with back-
ward elimination using hospital/ED associated CINV
events as the outcome variable, and controlling for age,
CCI, and cyclophosphamide treatment days, found the
palonosetron group to have significantly lower risk
(38%) of outcome [Odds Ratio (OR) = 0.62, p = 0.0035;
Table 3]. In addition, a higher CCI score was found to
significantly increase the risk of outcome, while more
CT days was associated with a reduced risk (p< 0.05,
Table 4). In the LC-carboplatin cohort, the palonosetron
group experienced 29% lower risk of hospital/ED asso-
ciated CINV events than the older 5-HT3 RA group
(OR= 0.71, p = 0.0006). The model with LC-carboplatin
cohort found that a higher CCI score increased the risk
of outcome, while females and patients with more carbo-
platin treatment days experienced lower risk (p< 0.05;
Table 4). Similarly, the palonosetron group in the LC-
cisplatin cohort experienced a 29% reduced risk of hos-
pital/ED associated CINV events as compared to the
older 5-HT3 RA group (OR= 0.71, p = 0.0330, Table 4).comes
n-treated lung cancer Cisplatin-treated lung cancer
RAs
Palonosetron P All Older
5-HT3 RAs
Palonosetron P
1,806 1,154 764 390
) 6.1 (3.6) NS 5.8 (4.3) 6.3 (4.7) 4.9 (3.2) <0.0001
.2) 8.5 (5.4) <0.0001 13.0 (8.0) 15.3 (8.0) 8.5 (5.6) <0.0001
.4) 7.7 (4.9) <0.0001 10.9 (6.9) 13.1 (6.8) 6.4 (4.4) <0.0001
) 0.2 (1.2) 0.0004 0.6 (2.0) 0.7 (2.1) 0.6 (1.9) 0.0499
2.8) 171 (9.5) 0.0005 230 (19.9) 166 (21.7) 64 (16.4) 0.0324
spital/ED associated CINV events, where the nonparametric Wilcoxon and




Lung cancer (N= 4497)
Cisplatin-treated
lung cancer (N = 1154)
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value






Gender (male as reference)




(in breast cancer) or carboplatin















NA: not applicable, NS: Not significant.
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son regression analyses with days of hospital/ED asso-
ciated CINV events as the dependent variable found that
the palonosetron group incurred significantly fewer
CINV days as compared to the older 5-HT3 RA groups
after controlling for age, CCI score, and CT treatment
days. In the BC cohort, the total days with hospital/ED
associated CINV events in the palonosetron group was
almost half as much (52.6%) of those incurred by
patients in the older 5-HT3 RA group (95% CI, 35.4%-
78.1%, p = 0.0015, Table 5). Similar to the findings in the
logistic regression, a higher CCI score also significantly
increased CINV days while more CT days was asso-
ciated with a reduced number of CINV days (p< 0.05)
in the BC cohort. In the LC-carboplatin cohort, the total
CINV days experienced by the palonosetron group was
70.9% of those incurred by the older 5-HT3 RA group
while a higher CCI score increased and more chemo-
therapy days reduced CINV days (p< 0.05). In the LC-
cisplatin cohort, the model did not show a significant
difference between the two 5-HT3 RA groups in CINV
days, although the negative coefficient for the palonose-
tron group denotes a decrease in CINV days (Table 5).
Discussion
There are relatively few studies in the literature that
have evaluated the implications of pharmacy administra-
tion step therapy policies on clinical and economic out-
comes [15]. Specifying two scenarios, one deals with
initiating antiemetic therapy on palonosetron, a second
generation 5-HT3 RA, and maintaining this regimen
throughout the patient’s chemotherapy experience ver-
sus another dealing with initiating antiemetic therapy
with an older 5-HT3 RA, regardless of whetherpalonosetron or an older 5-HT3 RA was used subse-
quently, a natural experiment was formulated utilizing
real-world claims data. Comparing the subsequent CINV
events associated with hospital/ED admissions of pa-
tients who were initiated and maintained on the respect-
ive 5-HT3 RA-based regimens supported an indirect
evaluation of a step therapy approach and formed the
basis of this investigation. The analysis focused on two
MEC cohorts, patients with breast cancer receiving a
cyclophosphamide-based regimen and patients with lung
cancer receiving carboplatin treatment, and one HEC
cohort of patients with lung cancer on cisplatin treat-
ment. In addition to the primary study end point of
CINV-associated hospital/ED events, a secondary out-
come addressed days with CINV events associated with
hospitalizations or ED admissions. The focus on hos-
pital/ED associated CINV was to capture the most costly
healthcare resources consumed resulting from uncon-
trolled CINV.
Among the breast cancer, lung cancer-carboplatin and
lung cancer-cisplatin cohorts, 48%, 60%, and 66% of the
patients, respectively, were started with an older 5-HT3
RA as the initial antiemetic to prevent CINV. The study
showed that the risk of one or more hospital/ED asso-
ciated CINV events was significantly lower in the palo-
nosetron groups as compared to the older, generic 5-HT3
RA groups, with reductions between 30-40%, depending
on the emetogenicity of the chemotherapy. In multiple
regression analyses, and for all three study cohorts, the
palonosetron groups experienced lower risk in the form
of reduced CINV events, fewer days with hospital/ED
events, fewer 5-HT3 RA claims, and fewer total antiemetic
claims than those incurred by the older 5-HT3 RA treated
groups.
Table 5 Results of the Poisson regression models on days of hospital/ED associated CINV events
Parameters Breast cancer (N= 3606) Carboplatin-treated lung cancer (N= 4497) Cisplatin-treated lung cancer (N= 1154)
Regression coefficient (95% CI) P value Regression coefficient (95% CI) P value Regression coefficient (95% CI) P value
Age -0.0032 (-0.0219; 0.0155) 0.7354 -0.0008 (-0.0120; 0.0105) 0.8961 -0.0149 (-0.0325; 0.0027) 0.0968
CCI 0.2529 (0.0572; 0.4486) 0.0113 0.0448 (0.0087; 0.0810) 0.0151 0.0747 (0.0182; 0.1312) 0.0096
Gender (male as reference)
Female NA -0.1815 (-0.4202; 0.0573) 0.1363 -0.0132 (-0.3975; 0.3711) 0.9463
Days with cyclophosphamide
(in breast cancer) or carboplatin
(in lung cancer) treatment
-0.3800 (-0.5600; -0.2000) <.0001 -0.0483 (-0.0848; -0.0118) 0.0095 0.0113 (-0.0263; 0.0488) 0.5561
Antiemetic regimen
(older 5-HT3 RAs as reference)
Palonosetron -0.6431 (-1.0391; -0.2471)* 0.0015 -0.3436 (-0.5871; -0.1001)* 0.0057 -0.0373 (-0.4456; 0.3711) 0.8580
* In Poisson regression, the exponential of coefficient indicates the ratio of the comparison groups in outcome. The exponential of the coefficient of antiemetic regimen (-0.6431) was 0.526 in the BC cohort, indicating
the average CINV-hospitalization/ED days of palonosetron group was about 52.6% of that of the comparison group (older 5-HT3 RAs). The exponential of the coefficient of antiemetic regimen (-0.3436) was 0.709 in the
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clinical outcomes found in our retrospective analysis
corroborates data obtained from clinical trials. In both
settings, palonosetron was associated with a significantly
reduced risk of developing CINV events as compared
with the older 5-HT3 RAs. Additionally, a recently pub-
lished study that compared palonosetron and ondanse-
tron using medical record review found that in patients
with gynecological cancers treated with cisplatin, palo-
nosetron was associated with a trend of a lower risk of
CINV-related hospital readmission than ondansetron
[20].
Difference in index date for patients with breast cancer
from that used in patients with lung cancer reflects the
nature of the two clinical conditions. Since patients with
breast cancer were included contingent upon having
received surgical interventions with each patient having
different time interval from initial diagnosis to surgical
intervention and initiation of chemotherapy, an index
date with time of diagnosis would consistently depict the
patients’ clinical severity of this study cohort. Despite
differences in the index dates among the three cancer
cohorts, the impact on outcome would be neglible, be-
cause all the comparisons made were between groups
within the same cohort instead of between cohorts.
A recent publication summarized research on the abil-
ity of interventions to contain drug expenditures in man-
aged care settings over the past 10 years [15]. A total of
63 studies were identified, with seven focusing on step
therapy type interventions. The report found that in
some instances, savings in drug expenditures through
step therapy are associated with an increase in total plan
spend. The authors suggested that additional research
was needed, especially with respect to the impact of these
types of interventions on clinical and humanistic out-
comes [15]. This study adds to the current body of know-
ledge by focusing on the clinical impact of step therapy
as it relates to the 5-HT3 RA antiemetic drug class in a
particularly vulnerable patient population.
The palonosetron groups in two of the three cohorts
were less likely to have pharmacy benefits. We have
reported significance in terms of less antiemetic use in
these groups, however due to the nature of claims data,
it is unclear whether or not some additional prescrip-
tions were actually written, but not filled by the patients.
As such, it is possible that patients with lower socioeco-
nomic status (SES) may not have been adequately stud-
ied. This limitation is relevant to the extent that lower
SES, independent of taking or not taking palonosetron,
may explain some of the differences in the CINV experi-
ence. Additionally, it may be possible to infer that provi-
ders may have prescribed differently if insurance
companies provided coverage for the otherwise not con-
sidered anti-emetic alternatives.In the current study, all older 5-HT3 RAs were com-
bined into one group, in part to simplify the study de-
sign, but also based on reported findings that patients
on HEC who were treated with dolasetron, granisetron,
or ondansetron, demonstrated no significant difference
in antiemetic efficacy. [21]. Fewer chemotherapy treat-
ment days, in and by itself, was associated with higher
risk for CINV experience, because of the higher chemo-
therapy dose used in a shorter time frame. We reported
that in the palonosetron treated group, there were both
fewer days of chemotherapy and lower risk of CINV.
This outcome would most likely be attributed to palono-
setron treatment lowering the risk for CINV, in spite of
the higher potential for the risk of CINV experience
when a course of chemotherapy was given within a
shorter time frame. Our results suggest that initiating
and maintaining patients on palonosetron throughout all
chemotherapy treatment cycles, rather than implement-
ing a step therapy of initiating patients first on any one
of the older 5-HT3 RAs, reduced the number of antie-
metic medications and simultaneously achieved fewer
hospital/ED associated CINV events.Limitations
This study had the inherent limitations associated with
retrospective analyses. Patterns of 5-HT3 RA therapies
were not solely responsible for the CINV outcomes
reported. Additional important explanatory variables are
not captured in claims data. These include race, alcohol
consumption, cancer staging, and history of motion sick-
ness, to name a few. Although efforts were made to de-
lineate the relationship between timing of outcomes and
5-HT3 RA use, the temporal relationship between these
two variables hinged on when providers submitted
related claims.
Selection bias or confounding by indication could also
be present in this study. The calculated CCI score and
the employed multiple regressions may have adjusted for
some but not all of the differences between the study
groups. Finally, the claims dataset used in this study was
mainly employer-based, thus potentially limiting the
generalizability of the study findings since the elderly
population would not have been adequately represented.Conclusion
Consistently across three separate cancer cohorts, initi-
ating and maintaining patients on palonosetron was
found associated with significant reduction in the risk
and frequency of CINV events associated with
hospitalization/ED admissions relative to what was
achieved when older 5-HT3 RAs were used as the initial
antiemetic. Results from this retrospective analysis sug-
gest that step therapy approaches with respect to 5-HT3
Lin et al. BMC Health Services Research 2012, 12:215 Page 9 of 9
http://www.biomedcentral.com/1472-6963/12/215RAs should take into consideration the implications for
costly downstream CINV events.
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